Silencing of CD44 gene expression in human 143-B osteosarcoma cells promotes metastasis of intratibial tumors in SCID mice

Gvozdenovic, Ana; Arlt, Matthias J E; Campanile, Carmen; Brennecke, Patrick; Husmann, Knut; Born, Walter; Muff, Roman; Fuchs, Bruno

Abstract: Osteosarcoma (OS) is the most frequent primary malignant bone cancer in children and adolescents with a high propensity for lung metastasis. Therefore, it is of great importance to identify molecular markers leading to increased metastatic potential in order to devise more effective therapeutic strategies that suppress metastasis, the major cause of death in OS. CD44, the principal receptor for the extracellular matrix component hyaluronan (HA), is frequently found overexpressed in tumor cells and has been implicated in metastatic spread in various cancer types. Here, we investigated the effects of stable shRNA-mediated silencing of CD44 gene products on in vitro and in vivo metastatic properties of the highly metastatic human 143-B OS cell line. In vitro, CD44 knockdown resulted in a 73% decrease in the adhesion to HA, a 57% decrease in the migration rate in a trans-filter migration assay, and a 28% decrease in the cells’ capacity for anchorage-independent growth in soft agar compared to the control cells, implicating that CD44 expression contributes to the metastatic activity of 143-B cells. However, making use of an orthotopic xenograft OS mouse model, we demonstrated that reduced CD44 expression facilitated primary tumor growth and formation of pulmonary metastases. The enhanced malignant phenotype was associated with decreased adhesion to HA and reduced expression of the tumor suppressor merlin in vivo. In conclusion, our study identified CD44 as a metastasis suppressor in this particular experimental OS model.

DOI: https://doi.org/10.1371/journal.pone.0060329

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-86181
Published Version

Originally published at:
Gvozdenovic, Ana; Arlt, Matthias J E; Campanile, Carmen; Brennecke, Patrick; Husmann, Knut; Born, Walter; Muff, Roman; Fuchs, Bruno (2013). Silencing of CD44 gene expression in human 143-B osteosarcoma cells promotes metastasis of intratibial tumors in SCID mice. PLoS ONE, 8(4):e60329. DOI: https://doi.org/10.1371/journal.pone.0060329
Silencing of CD44 Gene Expression in Human 143-B Osteosarcoma Cells Promotes Metastasis of Intratibial Tumors in SCID Mice

Ana Gvozdenovic, Matthias J. E. Arlt, Carmen Campanile, Patrick Brennecke, Knut Husmann, Walter Born, Roman Muff, Bruno Fuchs

Abstract

Osteosarcoma (OS) is the most frequent primary malignant bone cancer in children and adolescents with a high propensity for lung metastasis. Therefore, it is of great importance to identify molecular markers leading to increased metastatic potential in order to devise more effective therapeutic strategies that suppress metastasis, the major cause of death in OS. CD44, the principal receptor for the extracellular matrix component hyaluronan (HA), is frequently found overexpressed in tumor cells and has been implicated in metastatic spread in various cancer types. Here, we investigated the effects of stable shRNA-mediated silencing of CD44 gene products on in vitro and in vivo metastatic properties of the highly metastatic human 143-B OS cell line. In vitro, CD44 knockdown resulted in a 73% decrease in the adhesion to HA, a 57% decrease in the migration rate in a trans-filter migration assay, and a 28% decrease in the cells’ capacity for anchorage-independent growth in soft agar compared to the control cells, implicating that CD44 expression contributes to the metastatic activity of 143-B cells. However, making use of an orthotopic xenograft OS mouse model, we demonstrated that reduced CD44 expression facilitated primary tumor growth and formation of pulmonary metastases. The enhanced malignant phenotype was associated with decreased adhesion to HA and reduced expression of the tumor suppressor merlin in vivo. In conclusion, our study identified CD44 as a metastasis suppressor in this particular experimental OS model.

Introduction

Osteosarcoma (OS) is the most common primary malignant bone cancer in children and adolescents, characterized by the presence of spindle-like tumor cells which produce immature bone or osteoid. The overall incidence is three patients/million/year with the median peak at the age of 16 [1]. OS has a high propensity for metastasis to the lung and bones. Twenty percent of the patients have detectable metastases already at the time of diagnosis and eighty percent of the patients who initially present with localized disease subsequently develop metastases [2,3]. Significant clinical improvements over the past several decades through the use of combined chemotherapy and surgery have led to a dramatic increase in the survival of patients with localized disease. However, patients with metastatic or recurrent disease continue to have a very poor prognosis, with <20% long term survival [3]. Therefore, it is of great importance to elucidate the molecular mechanisms of OS metastasis. A detailed understanding of these mechanisms will in the future guide the design of novel treatment strategies and the development of corresponding metastasis suppressive compounds that will finally help to improve the survival of OS patients.

Previous studies revealed evidence for important functions of CD44 gene products during metastatic spread of numerous types of tumors [4] and respective proteins were therefore considered as targets for anti-metastatic treatment. Moreover, several reports have described prognostic power of CD44 gene products in different cancer types [5,6,7]. CD44 gene products are transmembrane proteoglycans, which act as cell-cell and cell-matrix adhesion molecules and principle receptors of hyaluronan (HA) [8]. They exist as multiple isoforms that are generated from a single primary gene transcript by alternative splicing combined with varying posttranslational glycosylation [9]. As a result, the extracellular domains of CD44 isoforms consist of variable regions, encoded by variant exons, and are glycosylated to different extents. The standard isoform CD44s, also described as CD44H (hematopoietic), is the smallest CD44 gene product and does not contain any of the variable extracellular regions encoded by the variant exons. The structural differences in the extracellular domains of the CD44 isoforms largely define a wide range of biological functions in development, inflammation, haematopoiesis, wound healing, immune response and cancer [4]. In tumor biology, evidence has accumulated that metastasis in different types of cancer is directly or inversely related to the expression of
CD44 gene products, depending on the expression pattern of CD44 isoforms and on the organ of origin. Several studies have shown up-regulated expression of CD44 isoforms in many human tumors, including gastric cancer, pancreatic cancer, lung and renal cell cancer [6,10,11,12]. Some reports point to important functions of CD44s in tumor progression [13]. However, in other tumor types, such as neuroblastoma and prostate cancer, the absence of CD44 gene products correlated with poor prognosis [7,14]. In prostate carcinoma cells, CD44 was even considered as a metastasis-suppressor gene [4,15]. Thus, the functions of CD44 gene products in tumor biology are controversially discussed.

Little is known on potential functions of CD44 gene products in OS pathophysiology and in OS metastasis in particular. Two immunohistochemical studies of OS tissue specimens revealed discrepant results. Kim et al. reported that overexpression of the CD44v5 isoform (CD44s with an additional amino acid sequence in the extracellular domain encoded by variant exon 5) in tumor tissue correlated significantly with metastatic disease and, consequently, lower survival rates of the patients [16]. In the tumor samples analyzed by Kuryu et al., on the other hand, a poor prognosis for OS patients correlated with overexpression of the CD44 isoforms that contain in the extracellular domain the amino acid sequence encoded by variant exon 6 (CD44v6) [17]. In both studies, immunostaining with CD44 antibodies detecting all expressed CD44 isoforms in tumor tissue together (pan CD44 antibodies) was not a prognostic indicator.

As outlined before, HA is the principle ligand of CD44 gene products. In OS, a few studies with established OS cell lines revealed evidence for a tumor promoting effect of HA. Hosono et al. showed that in vitro and in vivo tumorigenic properties of the OS cell lines MG63 and LM8 were inhibited by HA oligosaccharides that perturbed the HA-rich pericellular matrix [18]. A study performed by Nishida et al. showed diminished retention of HA and inhibition of tumorigenicity of MG63 OS cells upon anti-sense inhibition of HA synthase (HAS)-2 [19]. HAS-3-derived HA enhanced the cellular properties required for OS metastasis, such as proliferation, invasion and degradation of extracellular matrix in vitro [20].

The controversial discussions on the relevance of CD44 gene products in cancer biology in general and the limited knowledge on their biological functions in OS and metastasis in particular prompted us to perform the here reported CD44 silencing study in an intratibial OS xenograft model in SCID mice that makes use of the human highly metastatic 143-B cell line and reproduces the tumorigenic properties of the OS cell line in the intratibial tumor growth and lung metastasis in SCID mice [21].

CD44 Silencing Promotes Osteosarcoma Metastasis

**Materials and Methods**

Cell culture and transduction

Human 143-B OS cells (CRL-8303) were obtained from American Type Culture Collection (ATCC, Rockville, MD). The cells were cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1) medium (Invitrogen; Carlsbad, CA), supplemented with 10% heat-inactivated FCS (GIBCO, Basel, Switzerland), at 37°C in a humidified atmosphere of 5% CO₂/95% air. CD44 expression was stably silenced by retroviral expression of shRNA in 143-B cells that were transduced with a LacZ gene for tumor cell identification by X-gal staining in mouse tissues [22]. Retroviral constructs in the pSirenRetroQ vector (Clontech; Palo Alto, CA) coding for CD44 transcript-targeting shRNA (shCD44) and for non-targeting control shRNA (Ctrl shRNA) were kindly provided by Prof. Ivan Stamenkovic (Lausanne, Switzerland) [22]. Retroviral particles containing shCD44 or Ctrl shRNA constructs or the empty pSirenRetroQ vector (EV) with a puromycin resistance gene were produced in HEK293-T cells according to a protocol reported by Arlt et al. [23]. LacZ-transduced 143-B cells were infected with retroviruses by incubation for 48 h in virus-containing medium supplemented with 8 μg/ml polybrene. Retrovirus infected cells were subsequently selected and maintained in cell culture medium containing 2 μg/ml puromycin (Invitrogen). The selection revealed LacZ-expressing 143-B EV, 143-B shCD44 and 143-B Ctrl shRNA sublines. Prior to animal experiments, 143-B shCD44 cells were further enriched by incubation in tissue culture medium on HA-coated plates (100 μg/cm²; Sigma Aldrich, St. Luis, MO) at 37°C for 10 min that removed cells with inefficiently silenced CD44 expression. Non-adherent 143-B shCD44 cells in the supernatant were collected and used for animal experiments.

**Immunocytochemistry**

Cells were allowed to grow to subconfluence on glass coverslips in 24-well plates. After washing with PBS, the cells were fixed with 4% formalin in PBS at room temperature (RT) for 20 min. Permeabilization and non-specific antibody binding to cell monolayers were achieved by preincubation at RT for 30 min in DMEM/F12 (1:1) medium containing 0.1% BSA and 0.1% saponin (blocking medium). The cells were then incubated at RT for 2 h with the primary pan CD44 antibody (Hermes3, kindly provided by Dr. Sirpa Jalkanen, Turku, Finland; 2 μg/ml in blocking medium). After extensive washing with blocking medium, secondary Alexa Fluor 546-labeled antibodies to mouse IgG (Invitrogen) at 1:200 final dilution were added and the cells incubated in the dark for 30 min. F-actin was stained with Alexa Fluor 488-labeled phalloidin (Invitrogen) and cell nuclei were visualized with DAPI. The coverslips were then washed with PBS and dipped in H₂O and then mounted in Immomount (ThermoScientific; Waltham, MA). Fluorescence was examined with a Nikon Eclipse E600 microscope equipped with appropriate filter blocks (Nikon Corporation, Tokyo, Japan).

**Western blot analysis**

Cells were lysed by incubation at 4°C for 1 h on a moving carrousel in lysis buffer consisting of 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS), 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride (PMSF) and 10 mg/ml aprotinin. Cellular debris were pelleted by centrifugation at 16000g and 4°C for 20 min. Equal amounts of proteins in supernatants were separated by 8% SDS-PAGE and then blotted onto Hybond-ECL membranes (GE Healthcare, UK). CD44 and β-actin were detected with mouse monoclonal Hermes3 antibodies (1 μg/ml) and antibodies to β-actin (Chemicon, Dietikon, Switzerland, final dilution 1:10000), respectively. HRP-conjugated secondary antibodies were purchased from Santa Cruz Biotechnologies. Peroxidase activity was visualized with Immobilon chemoluminescence substrate (Millipore, Billerica, MA) and a VersaDoc™ Imaging System (Bio-Rad; Hercules, CA).
Adhesion assay

Adhesion assays were performed in 96-well plates. The wells were coated with 100 μl per well of 1 mg/ml high molecular weight HA diluted in PBS (333 μg/cm²) of HMW-HA (Sigma-Aldrich) at 4°C overnight. They were then washed with PBS and blocked with heat-denatured (HD) 1% BSA in PBS at RT for 1 h. Non-coated wells or wells coated with HD-BSA alone were used as controls. Cells grown to subconfluence were detached with accutase (Sigma-Aldrich) and 10⁴ cells per well were seeded in triplicates and allowed to adhere at 37°C for 30 min. Non-adherent cells were removed by washing and adherent cells were then fixed with 10% formalin in PBS at RT for 15 min and subsequently stained with 0.05% crystal violet in H₂O at RT for 15 min. Photos of an area of 3.6 mm² were taken with an AxioCam MRm camera connected to the Zeiss Observer.Z1 inverted microscope adjusted to 4× magnification. The number of adherent cells was determined with ImageJ software. The percentage of adherent cells was calculated from the total number of adherent cells per well divided by the total number of seeded cells and multiplied by 100. The percentage of adherent 143-B Ctrl shRNA and 143-B shCD44 cells was normalized to the percentage of adherent 143B EV cells set to 100%. The data of three independent experiments are presented.

Migration assay

Transwell migration assays were performed as recently reported [23]. Briefly, 5–10 × 10⁴ cells were allowed to migrate at 37°C for 6 h through 8 μm porous polycarbonate filters of cell culture inserts (Becton Dickinson, San Jose, CA) fitting into 24-well plates. Cells remaining on the upper side of the filter insert were considered as non-migrating cells and removed by wiping with a cotton swab. Migrated cells on the lower side of the filters were fixed with 10% formalin in PBS, permeabilized with 50 μM digitonin (Calbiochem, Switzerland) and stained with 300 nM Picogreen in PBS (Invitrogen) at RT for 15 min. Three randomly selected filter areas of 0.58 mm² per insert (two filters per cell line) were photographed with an AxioCam MRm camera connected to the Zeiss Observer.Z1 inverted microscope equipped with an appropriate filter block for blue excitation and set to 10× magnification. The number of cells that migrated to the lower side of the polycarbonate filters was determined with ImageJ software. The results are presented as described for the adhesion assay. The experiments were carried out at least three times.

Proliferation assay

Subconfluent, logarithmically growing cells were trypsinized and 5 × 10⁴ cells in 2.5 ml of cell culture medium were seeded in triplicates in 12.5 cm² flasks and allowed to grow for between 1 and 5 days and collected at one-day intervals by trypsinization. The cell number/flask was determined by counting aliquots of harvested cells in a Neubauer chamber. The equation N = N₀ eᵏ was used to calculate the doubling time during logarithmic growth.

Soft agar colony formation assay

Experiments were carried out in 6-well plates. A bottom agar layer in individual wells was generated with 1.3 ml of 0.5% DNA grade agarose (Promega, Madison, WI) in cell culture medium. The plates were kept at 4°C until use. 2 × 10⁴ cells in 1.3 ml of 0.55% agarose in cell culture medium were seeded per well in triplicates on top of the bottom agar layer. The cells were cultured at 37°C for 24 h before 2 ml per well of cell culture medium with penicillin/streptomycin/amphotericin B (PSA, 1:100; Invitrogen) were added. The medium was replaced every 3 days and the cells were cultured for 14 days. Cell colonies were stained with 2 ml 0.005% crystal violet at 4°C overnight. Three randomly selected areas per well were photographed with an AxioCam MRm camera connected to a Zeiss Observer.Z1 inverted microscope set to 4× magnification. ImageJ software was used to determine the number and the size distribution of colonies. The mean number of colonies per well formed by the individual manipulated cell lines was calculated and normalized to that of 143-B EV cells set to 100%. The experiments were repeated four times in triplicates.

Intratibial xenograft OS mouse model

Eight week old SCID/CB17 immunocompromised mice were obtained from Charles River Laboratories (Sulzfeld, Germany) at least 14 days before the start of the experiment. The animal experiments were approved (License Number 129/2009) by the Ethics Committee of the Veterinary Office of the Kanton Zürich and were conducted in accordance with the guidelines of the “Schweizer Bundesamt für Veterinarwesen”. On day 0 of the experiments, 2 × 10⁵ of 143-B cells (engineered as described) in 10 μl of PBS/0.05% EDTA containing Matrigel (Becton-Dickinson; Franklin Lake, NJ) were injected intratibially. After the injections, the health condition of the mice was closely monitored. Tumor development was examined weekly by X-ray with an MX-20 DC Digital Radiography System (Faxitron X-Ray Corporation, Lincolnshire, IL) and by caliper measurements of the length and the width of the tumor leg from which the tumor volume was calculated with the formula V = length × width²/2. The mice were sacrificed 21 days after tumor cell injection and in situ lung perfusion was performed as described [23]. Organs collected at sacrifice were fixed in 2% formaldehyde at RT for 30 min, washed three times with PBS and LacZ gene expressing tumor cells were stained with 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-Gal) staining solution at 37°C for at least 3 h as described [24,25]. The indigo-blue stained metastases on the lung surface were counted under the microscope. The animal experiments were carried out three times. The data of a representative experiment are shown.

Immunohistochemistry

Tumors and lungs previously fixed in 4% formaldehyde were dehydrated through serial incubation in 70%, 96%, 100% ethanol and xylene and then embedded in paraffin. Sections of 6 μm were mounted onto slides, deparaffinized and rehydrated and then heated in 0.1 M citrate buffer (pH 5.8) for antigen retrieval. Endogenous peroxidase was inactivated by incubation of the tissue sections in 3% H₂O₂ at RT for 10 min. Non-specific binding of antibodies to tissue sections was blocked by incubation at RT for 1 h in Tris buffered saline (TBS; 50 mM Tris, 150 mM NaCl, pH 7.4) that contained 10% goat serum (Vector Laboratories; Burlingame, CA) and 0.1% Tween (Sigma Aldrich). Primary antibodies to CD44 antibodies (2 μg/ml in blocking solution), and antibodies to merlin NF2 (Santa Cruz Biotechnologies; 4 μg/ml) and to Ki67 (Abcam; Cambridge, UK; 4 μg/ml) were then applied and the slides incubated at RT for 1 h. After washing with TBS, the slides were incubated with secondary biotinylated goat anti-mouse IgG (Vector; 1:200) at RT for 1 h. Slides incubated with secondary antibody alone served as negative controls. After another wash with TBS, the sections were incubated with avidin-conjugated peroxidase (ABC kit; Vector Laboratories) at RT in the dark for 30 min, washed again with TBS, and then incubated with the peroxidase substrate AEC (Dako; Glostrup, Denmark) for staining. Finally, the slides were briefly counterstained with hematoxylin. Recombinant mouse CD44 Fc chimera (R&D
Systems, Minneapolis, MN; 10 μg/ml) were used for the staining of HA in tissue sections with the standard protocol for immunostaining excluding antigen retrieval. For negative controls, tissue sections were treated with hyaluronidase (200 U/ml; Sigma Aldrich) at 37°C overnight prior to HA staining, or the CD44 Fc chimera were preincubated with HA (1 mg/ml; Sigma Aldrich) before application to the slides.

**Statistical analysis**

Differences between means were analyzed by the Student t-test and p<0.05 was considered significant. The results are presented as means ± SEM.

**Results**

shRNA-mediated silencing of the CD44 gene in the human metastatic 143-B OS cell line diminishes *in vitro* metastatic properties

An analysis in 143-B cells of the products derived from the CD44 gene revealed predominant expression of the standard CD44s isoform, a finding that was consistent with observations in other established as well as primary human OS cell lines (not shown). Based on the previously reported malignant phenotype of 143-B cells *in vivo*, which, upon intratibial injection, nicely reproduced the human disease with primary osteolytic bone lesion that metastasize to the lung [26], 143-B cells stably expressing a
Lactose (LacZ) gene were used to study the biological relevance of CD44 molecules in OS aggressiveness. Retroviral transduction of 143-B cells with a vector for stable expression of CD44 gene transcript-targeting shRNA revealed effective downregulation of CD44 gene-derived protein products in cell extracts and in the cell monolayers visualized by immunocytochemistry (Figure 1A and B). This was not observed in 143-B cells transduced with empty-vector retroviruses or with viruses producing non-specific control shRNA. Staining of actin filaments, on the other hand, clearly demonstrated that morphological features of the three cell lines were not affected by the described manipulations. This silencing of the CD44 gene in 143-B cells reduced their capacity to adhere to HA by 75 ± 7.3% (p<0.02) compared to that observed with 143-B EV cells (Figure 2A). The adhesion of 143-B Ctrl shRNA cells with maintained CD44 expression, on the other hand, was indistinguishable from that of 143-B EV cells. Similarly, the CD44 silencing observed in 143-B shCD44 cells reduced the migration rate by 57 ± 4.2% (p<0.0001) compared to that of 143-B EV cells, which was also indistinguishable from that of 143-B Ctrl shRNA cells (Figure 2B). Interestingly, CD44 silencing had no effect on proliferation of 143-B cells in 2D culture (Figure 2C). Cell cycle distribution assessed by propidium iodide staining followed by flow cytometry was identical in the respective cell line populations (Figure S1). The number of 143-B shCD44 cell colonies growing anchorage-independent in soft agar, on the other hand, was 28 ± 6% (p<0.02) lower than that of 143-B EV cells, which was comparable to that of 143-B Ctrl shRNA cells (Figure 2D). The size of growing colonies of the three cell lines in soft agar did not differ (not shown).

CD44 silencing in 143-B OS cells enhances their malignancy in SCID mice

The results of the in vitro characterization of the malignant properties of 143-B shCD44, - Ctrl shRNA and - EV cells suggested that stable shRNA-mediated silencing of the CD44 gene in 143-B cells might also affect the development in vivo of intratibial 143-B cell-derived primary tumors and lung metastasis. Three groups of SCID mice were therefore intratibially injected with 143-B shCD44, - Ctrl shRNA or - EV cells, respectively. Fourteen
days after tumor cell injection, similar osteolytic lesions, characteristic for 143-B cell-derived tumors, were recognized by X-ray in all three groups of mice (Figure 3A). Somehow unexpectedly, caliper measurements of the volume of the tumor legs over time revealed growth of intratibial primary tumors to a significantly \((p < 0.001)\) larger final size at sacrifice on experimental day 20 in mice injected with 143-B EV (EV) \((n = 9)\), 143-B Ctrl shRNA (Ctrl shRNA) \((n = 6)\) or 143-B shCD44 (shCD44) \((n = 9)\) cells. (C) Representative images and (D) quantification of X-gal stained (blue) metastases on whole-mounts of lungs collected from mice intratibially injected with 143-B EV (EV) \((n = 9)\), 143-B Ctrl shRNA (Ctrl shRNA) \((n = 6)\) or 143-B shCD44 (shCD44) \((n = 9)\) cells. Values are expressed as mean ± SEM; *, \(p < 0.05\).

doi:10.1371/journal.pone.0060329.g003

Figure 3. Effects of CD44 silencing on intratibial primary tumor growth and lung metastasis of 143-B OS cells in SCID mice. (A) Primary tumor development over time monitored by X-ray or (B) by tumor leg volume measurement at indicated time points in mice intratibially injected with 143-B EV (EV) \((n = 9)\), 143-B Ctrl shRNA (Ctrl shRNA) \((n = 6)\) or 143-B shCD44 (shCD44) \((n = 9)\) cells. (C) Representative images and (D) quantification of X-gal stained (blue) metastases on whole-mounts of lungs collected from mice intratibially injected with 143-B EV (EV) \((n = 9)\), 143-B Ctrl shRNA (Ctrl shRNA) \((n = 6)\) or 143-B shCD44 (shCD44) \((n = 9)\) cells. Values are expressed as mean ± SEM; *, \(p < 0.05\).

doi:10.1371/journal.pone.0060329.g003

In view of the discrepant malignant properties of 143-B shCD44 cells \textit{in vitro} and \textit{in vivo}, we assessed the expression of immunoreactive CD44 by immunohistochemistry with Hermes3 antibodies in primary tumor tissue and lung metastases derived from 143-B shCD44 cells and compared it with 143-B EV and 143-B Ctrl shRNA cell-derived tumors. This analysis demonstrated that
CD44 silencing was maintained in vivo in 143-B shCD44 cells (Figure 4C and I). The content of HA in the extracellular matrix of primary tumors, on the other hand, was indistinguishable in 143-B shCD44, -EV and -Ctrl shRNA cell-derived tumors, indicating that the levels of expression of CD44 gene products in 143-B cells did not affect extracellular HA deposition (Figure 4D-F). Interestingly, nuclear Ki67 immunostaining of proliferating tumor cells on primary tumor and lung paraffin sections showed a specific structure of primary tumors and lung metastases in mice bearing tumors depleted of CD44. 143-B shCD44 cells appeared to be in much looser contact in primary tumors and metastases than 143-B EV and 143-B Ctrl shRNA cells that formed remarkably denser malignant tissue than 143-B shCD44 cells (Figure 5A-F). The discrepant effects of CD44 silencing in 143-B cells observed in vitro and in vivo suggested different responses to this manipulation of cells in culture and in the living animal. Merlin, known to have tumor suppressor activity upon binding to the cytoplasmic domain of HA-interacting CD44 and thereby conferring cell growth arrest by contact inhibition [27], was considered as a candidate molecule contributing to the regulation of 143-B cell aggressiveness. Immunohistochemistry on intratibial primary tumor and lung paraffin sections indeed showed remarkably lower merlin protein levels in 143-B shCD44 than in 143-B EV and 143-B Ctrl shRNA cell-derived tumors and pulmonary metastases (Figure 5). Such differences in merlin protein levels in the three manipulated cell lines were not observed in vitro (not shown).

Discussion

Only a few studies addressed so far the biological relevance of CD44 expression in OS progression and metastasis and the results are controversial. One study did not find a correlation between CD44 protein expression and overall survival of OS patients [28] and in a second study, OS patients with high CD44 mRNA expression levels in primary tumor tissue were found to be more prone to have metastases than those with low expression [29]. Moreover, expression of distinctive CD44 isoforms was found to be correlated with unfavorable prognosis [16,17].

Here, we aimed at determining the role of CD44 in the human 143-B OS cell line with metastatic activity, which has robust endogenous CD44 expression and was selected as representative for OS. Therefore, we silenced the expression of CD44 gene products in 143-B cells and studied its impact in vitro and in vivo in an intratibial xenograft OS model in SCID mice. Interestingly, we

Figure 4. *Ex vivo* immunohistochemical analysis of shRNA mediated CD44 silencing in 143-B-lacZ OS cell-derived intratibial primary tumors and pulmonary metastases. Robust expression of immunoreactive CD44 observed in primary tumor (PT) tissue and pulmonary metastases (PM) derived from 143-B EV (EV) (A,G) and 143-B Ctrl shRNA (Ctrl shRNA) cells (B,H) was found suppressed in tumor tissue (C) and lung metastases (I) derived from 143-B shCD44 (shCD44) cells. Immunohistochemically detectable HA in PT (panels D-F) was not affected by CD44 silencing. The figure shows images of representative 6 μm paraffin sections with cell nuclei counterstained with hematoxylin. Bars, 100 μm.

doi:10.1371/journal.pone.0060329.g004
obtained discrepant findings \textit{in vitro} and \textit{in vivo}. \textit{In vitro}, stable shRNA-mediated CD44 knock-down significantly suppressed cell migration and growth in soft agar, implying that CD44 may contribute to the increased metastatic properties of 143-B cells. However, upon intratibial injection into SCID mice, 143-B cells with reduced CD44 expression even enhanced the malignant phenotype when compared to control cells. Mice bearing shCD44 xenografts developed larger primary tumors and had significantly increased number of pulmonary metastases when compared to those in control animals. In contrast to our \textit{in vitro} data, experiments \textit{in vivo} using the orthotopic xenograft mouse model identified CD44 as a metastasis suppressor gene in 143-B cells.

A plausible explanation for the enhanced metastatic activity in cells depleted of CD44 is their decreased adhesion to HA-rich extracellular matrices within primary tumors, consistent with the reduced adhesion to HA that we observed \textit{in vitro}. Furthermore, histology of tumor tissue revealed a low adhesive structure of 143-B shCD44 cells with wide intercellular gaps, as opposed to control transduced cells. The changes in adhesive properties of shCD44 cells may also have facilitated their mobility and enabled expansion and dissemination beyond the primary tumor site, ultimately leading to elevated metastatic potential. A study performed by Lopez et al. is in good agreement with our concept, in which they report that CD44 loss has a metastasis-promoting effect in a mouse model of spontaneously metastasizing breast cancer [30]. Moreover, the authors show that CD44/HA interactions inhibit invasion in a three-dimensional \textit{in vitro} invasion assay, suggesting that CD44 engagement with HA is protective against metastasis. Another explanation for the elevated malignant phenotype in 143-B cells with silenced CD44 is the observed loss of merlin protein expression \textit{in vivo} in these cells. Merlin is encoded by neurofibromatosis type 2 (NF2) gene and mutations and deletions of merlin underlie NF2 familial cancer syndrome, characterized by development of schwannomas, meningiomas and ependymomas [31]. As mutations of NF2 were also detected in other cancer types, it is considered as a tumor suppressor gene in a wide variety of tumor cells. Merlin is a multifunctional protein that regulates cell shape, proliferation, survival, motility and

Figure 5. CD44 silencing in 143-B OS cells reduced the density of proliferating cells in intratibial primary tumors and decreased the content of the tumor suppressor merlin in primary tumors and pulmonary metastases to immunohistochemically nearly undetectable levels. Representative images of 6 \textmu m paraffin sections of primary tumor (PT) (panels A-C and G-I) and of lung tissue with pulmonary metastases (PM) (panels D-F and J-L) stained for the proliferation marker Ki67 (panels A-F) and for merlin (panels G-L). Tissues were collected at sacrifice from SCID mice intratibially injected with 143-B EV (EV), 143-B Ctrl shRNA (Ctrl shRNA) or 143-B shCD44 (shCD44) cells. Bars, 100 \textmu m. doi:10.1371/journal.pone.0060329.g005
invasion. Interestingly, mice heterozygous for a mutation at the NF2 locus (Nf2+/-) are cancer prone, and develop a wide spectrum of tumors, most frequently OS, that display strikingly high metastatic proclivity, unlike the benign tumors in human patients with NF2 syndrome [32]. This study provided experimental support for the association of NF2 loss and elevated metastatic potential. Conversely to the observations in mice, in human OS patient samples NF2 mutations could not be found, whereas merlin protein could be detected, implicating the apparent differences between the mouse and human OS tumorigenesis [33]. Nevertheless, as merlin functions as a tumor and metastasis suppressor, accelerated tumor growth and enhanced ability to form metastases seen in the intratibial OS mouse model presented here may be the consequence of loss of merlin’s expression in 143-B shCD44 cells. In breast cancer, in which mutations are absent as in OS, the stability of merlin mRNA was found unaltered [34]. A recent report by Morrow et al. showed that the loss of merlin protein observed in breast cancer tissues occurs without any change at the transcript level and is as a result of proteasomal degradation induced by osteopontin initiated Akt-mediated phosphorylation of merlin [35]. Mechanisms underlying merlin loss in OS cells need yet to be elucidated. Additionally, merlin has been reported to reverse the Ras-induced malignant phenotype [36]. Given the fact that 143-B cells were generated through Ki-Ras transformation [37], we suggest that Ras-driven metastatic behavior is even more pronounced upon loss of merlin protein expression in vivo. Therefore, we cannot exclude the possibility of a cell-type specific effect of CD44 down-regulation on tumor and metastasis formation. However, CD44 may act as a metastasis suppressor by regulating merlin expression or function in a subset of OS where Ras signaling is involved. RHAMM, another HA binding protein that is expressed in 143-B or function in a subset of OS where Ras signaling is involved, may act as a metastasis suppressor by regulating merlin expression or function in metastasis in the above mentioned model was not due to an increase in CD44, but might be an additional player in our model.

Nedevetzki et al. showed that RHAMM can compensate for the loss of CD44 in binding HA, thereby supporting migration in a model of collagen-induced arthritis [38]. The observed compensation in the above mentioned model was not due to an increase in RHAMM expression, but rather by enhanced HA-induced signaling through RHAMM. The potential role of RHAMM in our OS model will be subject of a future detailed study. In conclusion, the findings of our study imply that CD44 is a negative regulator of metastasis in 143-B OS cells. The apparent discrepancy between in vitro and in vivo outcomes of CD44 knockdown on tumorigenic and metastatic properties of 143-B cells highlights the essential impact of the tumor environment on OS progression. CD44 functions as a metastasis suppressor gene in this particular experimental OS. Although the 143-B cells were representative for the expression pattern of CD44 gene products observed in other cell lines, the here observed effects of CD44 silencing might be particularly important in OS cells with up-regulated Ras activity. Future studies investigating CD44 expression in large cohorts of human tumor tissue samples will further contribute to the delineation of its role in OS.

Supporting Information

Figure S1 Cell cycle analysis of 143-B EV, 143-B Ctrl shRNA or 143-B shCD44 cells. Cell cycle progression was measured by propidium iodide (PI) staining using flow cytometry. Briefly, cells were trypsinized, washed once with cold PBS and resuspended in 300 μl of cold PBS. Subsequently, cells were fixed in ice cold ethanol and stored at −20°C overnight. The next day, DNA was stained in PI/RNase staining buffer (BD Pharmingen AG, Allschwil, Switzerland) at 37°C for 30 min in the dark. The samples were analysed on a FACS machine (Calibur, BD) and the cell cycle distribution was calculated using FlowJo software. The values indicate the mean ± SEM of six analyses from two independent samples. (TIF)

Acknowledgments

We thank Prof. Ivan Stamenkovic (Department of Experimental Pathology, University of Lausanne) for providing CD44 silencing and control constructs and helpful discussion and Dr. Sirpa Jalkanen (Turku, Finland) for providing Hermes3 antibody. We thank Dr. Monika Hilbe and Kati Zlinszky (Institute of Veterinary Pathology, Zurich) for the help in immunohistochemistry stainings of hyaluronan and we thank Josefine Bertz and Christopher Buller for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: AG RM BF WB. Performed the experiments: AG MJEA CC PB RM. Analyzed the data: AG. Contributed reagents/materials/analysis tools: KH. Wrote the paper: AG RM BF WB.

References

1. Picci P (2007) Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2: 6.
2. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. (1986) The Effect of Adjunct Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity. New England Journal of Medicine 314: 1600-1606.
3. Marina N, Gehbard M, Teot L, Gorlick R (2004) Biology and Therapeutic Advances for Pediatric Osteosarcoma. Oncology 9: 422-441.
4. Ponta H, Sherman L, Herrlich PA (2000) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 1: 35-45.
5. Wielenga VJ, Heider KH, Offerhaus GJ, Adolfs GR, van den Berg FM, et al. (1993) Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756.
6. Lim S, Young A, Paner G, Amin M (2000) Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Archiv 452: 49-55.
7. Shirvelman E, Bishop JM (1991) Expression of CD44 variant isoforms correlates with the metastatic potential of osteosarcoma. Orphanet J Rare Dis 2: 6.
8. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313.
9. Marbaha R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 213-231.
10. Heider K-H, Dammrich J, Siroos-Angel P, Muller-Hermelink H-K, Vollmer HP, et al. (1993) Differential Expression of CD44 Splice Variants in Intestinal- and Diffuse-Type Human Gastric Carcinomas and Normal Gastric Mucosa. Cancer Research 53: 4197-4203.
11. Rall CJN, Rustgi AK (1995) CD44 Isoform Expression in Primary and Metastatic Pancreatic Adenocarcinoma. Cancer Research 55: 1831-1835.
12. Penno MB, Augut JT, Baylin SB, Mabry L, Linnoila RI, et al. (1994) Expression of CD44 in Human Lung Tumors. Cancer Research 54: 1301-1307.
13. Kannistra SA, Kansas GS, Niloff JD, DeFranzo B, Kim Y, et al. (1993) Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro Is Partly Mediated by CD44H. Cancer Research 53: 3830-3833.
14. Angelo M, De Marzo CB (1998) CD44 and CD44v6 downregulation in clinical prostate carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate. pp. 162-168.
15. Gao AC, Lou W, Dong JT, Isaacs JT (1997) CD44 Is a Metastasis Suppressor Gene for Prostatic Cancer Located on Human Chromosome 11p13. Cancer Research 57: 4964-4969.
16. Kim HS, Park YB, Oh JH, Jeong J, Kim C, et al. (2002) Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res 396: 164-190.
17. Kuro M, Ozaki T, Nishida K, Shihabara M, Kawai A, et al. (1999) Expression of CD44 variant isoforms in osteosarcoma. J Cancer Res Clin Oncol 125: 646-652.
18. Hosono K, Nishida Y, Knudson W, Knudson CB, Nourse T, et al. (2007) Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 171: 274-286.
19. Nishida Y, Knudson W, Knudson CB, Ishiguro N (2005) Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 307: 194-203.
20. Tofuku K, Yokouchi M, Murayama T, Minami S, Komiya S (2006) HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells. Int J Oncol 29: 173-183.
21. Reidy K, Campanile C, Muff R, Born W, Fuchu B (2012) mTHPC-Mediated Photodynamic Therapy is Effective in the Metastatic Human 143B Osteosarcoma Cells. Photochemistry and Photobiology 88: 721-727.
22. Janiszewska M, De Vito C, Le Bitoux MA, Fusco C, Stamenkovic I (2010) Transporter regulates nuclear import of CD44. J Biol Chem 285: 30548-30557.
23. Arlt MJ, Banke IJ, Wahrs DK, Puskas GJ, Steinmann F, et al. (2011) LacZ transgene expression in the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of micrometastasis. J Orthop Res 29: 938-948.
24. Arlt M, Kopitz C, Pennington C, Watson KLM, Krell H-W, et al. (2002) Increase in Gelatinase-specificity of Matrix Metalloproteinase Inhibitors Correlates with Antimetastatic Efficacy in a T-Cell Lymphoma Model. Cancer Research 62: 5543-5550.
25. Kruger A, Schirrmacher V, von Hoegen P (1994) Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells. Int J Cancer 58: 275-284.
26. Yuan J, Ossendorf C, Szatkowski JP, Bronk JT, Maran A, et al. (2009) Osteoblastic and Osteolytic Human Osteosarcomas can be Studied With a New Xenograft Mouse Model Producing Spontaneous Metastases. Cancer Investigation 27: 435-442.
27. Morrison H, Sherman LS, Legg J, Banine F, Isakke C, et al. (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15: 960-980.
28. Boldrini E, Peres SV, Morini S, de Camargo B (2010) Immunoexpression of Ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol 32: e213-217.
29. Xu-Dong S, Zan S, Shui-er Z, Li-na T, Wen-xi Y, et al. (2009) Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med 32: E180-188.
30. Lopez JJ, Camenisch TD, Stevens MV, Sands BJ, McDonald J, et al. (2005) CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 65: 6755-6763.
31. Stamenkovic I, Yu Q (2010) Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11: 471-484.
32. McClatchey AI, Sastone M, Crocker D, Guerra LF, et al. (1998) Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12: 1121-1133.
33. Stemmer-Rachamimov AO, Nielsen GP, Rosenberg AE, Louis DN, Jones D, et al. (1998) The NF2 gene and Merlin protein in human osteosarcomas. Neurogenetics 2: 73-74.
34. Morrow KA, Shevde LA (2012) Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochem Biophys Acta 1826: 400-406.
35. Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, et al. (2011) Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem 286: 40376-40385.
36. Tikoo A, Varga M, Ramesh V, Guerra L, Maruta H (1994) An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269: 23387-23390.
37. Rhim JS, Cho HY, Huebner RJ (1975) Non-producer human cells induced by murine sarcoma virus. Int J Cancer 15: 23-29.
38. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, et al. (2004) RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy. Proceedings of the National Academy of Sciences 101: 18081-18086.